Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.
作者信息
Mulder N H, Sleijfer D T, de Vries E G, Schraffordt Koops H, Willemse P H
机构信息
Department of Internal Medicine, University Hospital Groningen, The Netherlands.
出版信息
J Cancer Res Clin Oncol. 1990;116(3):301-2. doi: 10.1007/BF01612907.
Abstract
Twenty-one patients with disseminated malignant melanoma were treated with a combination of carboplatin and cytosine arabinoside. Two complete and three partial remissions occurred. No complete cross-resistance was found with a regimen containing 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC) in two patients. It is suggested that this regimen might be studied further as a second-line treatment for patients who fail on DTIC-containing treatment.
摘要
相似文献
1
Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.
J Cancer Res Clin Oncol. 1990;116(3):301-2. doi: 10.1007/BF01612907.
2
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
3
A systematic overview of chemotherapy effects in ovarian cancer.
Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420.
4
Platinum-containing regimens for metastatic breast cancer.
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
5
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
J Cancer Res Clin Oncol. 1989;115(1):93-5. doi: 10.1007/BF00391607.
6
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Cochrane Database Syst Rev. 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3.
7
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Br J Dermatol. 2025 Jan 24;192(2):316-326. doi: 10.1093/bjd/ljae401.
8
Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.
Invest New Drugs. 1991 Aug;9(3):277-80. doi: 10.1007/BF00176984.
9
Intermittent interferon and polychemotherapy in metastatic melanoma.
J Cancer Res Clin Oncol. 1995;121(3):175-80. doi: 10.1007/BF01198100.
10
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
引用本文的文献
1
Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
Med Oncol. 2001;18(3):189-95. doi: 10.1385/MO:18:3:189.
2
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Br J Cancer. 2000 Jun;82(11):1759-63. doi: 10.1054/bjoc.2000.1141.
3
Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.
Invest New Drugs. 1991 Aug;9(3):277-80. doi: 10.1007/BF00176984.
本文引用的文献
1
Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine.
Cancer Res. 1981 Jan;41(1):25-30.
2
Chemotherapy of malignant melanoma.
Cancer. 1972 Dec;30(6):1604-15. doi: 10.1002/1097-0142(197212)30:6<1604::aid-cncr2820300629>3.0.co;2-5.
3
Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro.
Cancer Treat Rep. 1986 Mar;70(3):409-10.
4
Cytarabine and cisplatin in advanced malignant melanoma.
Cancer Treat Rep. 1986 Dec;70(12):1441-2.
5
Phase II trial of carboplatin in advanced malignant melanoma.
Cancer Treat Rep. 1987 Feb;71(2):171-2.
6
In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II).
Cancer Res. 1988 Jan 1;48(1):117-21.
7
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
J Clin Oncol. 1987 Apr;5(4):574-8. doi: 10.1200/JCO.1987.5.4.574.
8
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
J Cancer Res Clin Oncol. 1989;115(1):93-5. doi: 10.1007/BF00391607.
9
"Platinum-pyrimidine blues" and related complexes: a new class of potent antitumor agents.
Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):287-300.
10
Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia.
Clin Pharmacol Ther. 1977 Jun;21(6):744-50. doi: 10.1002/cpt1977216744.
Zotero 插件